Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2020-08-27 Regulatory Filings
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19
Regulatory Filings Classification · 95% confidence The document is a short announcement (2349 characters) from Gentian Diagnostics AS stating that the results from a study involving their GCAL® calprotectin assay in relation to severe COVID-19 have been published in the "Journal of Infection". It details the findings but does not contain the full study or comprehensive financial data. Since the text is an announcement about the publication of external scientific information, and it does not fit the specific categories like ER (Earnings Release), IR (Interim Report), or AR (Audit Report), it best fits the general regulatory announcement category, RNS (Regulatory Filings), as a miscellaneous corporate update regarding research validation.
2020-08-27 English
Primary insider notification - Korr
Director's Dealing Classification · 99% confidence The document is titled 'Primary insider notification - Korr' and details a transaction where a Chief Scientific Officer (Erling Sundrehagen) sold shares of Gentian Diagnostics AS. It explicitly mentions the number of shares sold, the price, and the resulting ownership structure, including a lock-up agreement. This directly corresponds to the definition of Director's Dealing (insider trades by executives/directors). The Norwegian Securities Trading Act reference further confirms its regulatory nature regarding insider transactions.
2020-08-27 English
Primary insider notification
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Primary insider notification' concerning the sale of shares by a Chief Scientific Officer (Erling Sundrehagen) and associated companies. This type of filing reports personal share transactions by company directors and executives (insider trades). This directly matches the definition for Director's Dealing (DIRS). The document is short and contains specific transaction details, confirming it is the notification itself, not an announcement of a report.
2020-08-27 English
2nd quarter and first half 2020 report
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Gentian Diagnostics covering the second quarter and first half of 2020. It includes detailed financial statements, such as sales revenue, geographic and product splits, COGS, operating expenses, R&D expenses, earnings (EBITDA, net profit), balance sheet items, and cash flow analysis. It also provides an operational summary and outlook. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. Q2 2020
2020-08-21 English
2nd quarter and first half 2020 report
Investor Presentation Classification · 98% confidence The document is titled 'Q2 Presentation 2020' and contains detailed financial highlights for Q2 2020 and 1H 2020, including tables for Sales, COGS, OPEX, and Cash Flow. It also includes sections on growth opportunities, product pipeline (fPELA turbo, GCAL , CoV-2 Ab, G-1001), and an outlook. This structure is characteristic of an Investor Presentation (IP) used to communicate periodic financial results and strategic updates to investors, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). The document is clearly a presentation format, not a transcript or a formal report.
2020-08-21 English
2nd quarter and first half 2020 report
Report Publication Announcement Classification · 98% confidence The document explicitly states it is announcing the '2nd quarter and first half 2020 report' and provides key financial highlights (record sales revenues, growth percentages). This points towards an Earnings Release (ER) or an Interim/Quarterly Report (IR). However, the text is very short (1282 chars) and concludes with the statement: 'Please find the report and results presentation enclosed.' According to Rule #2 (The 'MENU VS MEAL' Rule), a short document announcing that the full report is attached or available elsewhere should be classified as a Report Publication Announcement (RPA). Since this document announces the release of the Q2/H1 report and presentation, RPA is the most appropriate classification, even though it contains some highlights.
2020-08-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.